“Today, on the basis of six metropolitan polyclinics, we began a clinical study of a nasal vaccine developed by the Generium company,” said Anastasia Rakova, deputy mayor of the city.
In total, 660 people will take part in the study, including about 400 in Moscow medical institutions, the rest in 11 centers throughout Russia.
It is noted that the vaccine is identical in composition of active substances to Sputnik V.
Rakova said that earlier, on the basis of Moscow polyclinics, a study of the nasal vaccine of the N.F.
Gamaleya.
It was previously reported that clinical trials of the EpiVacCoron-N vaccine at the Vector Research Center in people over 60 years of age will begin in February and will last 42 days.